Related Experiment Videos
Recombinant factor VIIa in joint and muscle bleeding episodes
1Novo Nordisk, Gentofte, Denmark.
Haemostasis
|January 1, 1996
Summary
Recombinant factor VIIa (rFVIIa) effectively treats bleeding episodes in hemophilia patients with inhibitors. This therapy improves hemostasis and reduces infection risk, showing high response rates in joint and muscle bleeds.
Area of Science:
- Hematology
- Pharmacology
- Biotechnology
Background:
- Hemophilia patients with inhibitors present unique treatment challenges.
- Traditional treatments carry risks of blood-borne infections.
- Recombinant factor VIIa (rFVIIa) offers a potential alternative.
Purpose of the Study:
- To evaluate the efficacy and safety of rFVIIa in hemophilia patients with inhibitors.
- To assess rFVIIa's effectiveness in treating joint and muscle bleeding episodes.
- To determine rFVIIa's impact on inhibitor titre levels during immune tolerance therapy.
Main Methods:
- Retrospective analysis of rFVIIa administration in 111 patients.
- Total of 494 bleeding episodes (joint and muscle) documented.
- Investigator-based evaluation of treatment response (excellent/effective).
Main Results:
- rFVIIa demonstrated high efficacy in treating bleeding episodes.
- Excellent/effective response rates were 79% for joint bleeds and 65% for muscle bleeds.
- rFVIIa was effective in patients undergoing immune tolerance and did not alter inhibitor titres.
Conclusions:
- rFVIIa is an effective treatment for hemophilia patients with inhibitors.
- It improves hemostasis and mitigates the risk of transfusion-related infections.
- rFVIIa is a valuable therapeutic option for bleeding management in this patient population.